BioNTech secured a leading candidate in the race one year ago by paying Biotheus $55 million upfront for the rights to ...
The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...
In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes.
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is ...
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...